Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3341972

NC(=O)c1cccc(-c2ccc(CNCCc3ccccc3)cc2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 8/20 0.58
OPRM1 P35372 4/20 0.55
OPRD1 P41143 4/20 0.55
OPRK1 P41145 4/20 0.55
HDAC1 Q13547 3/20 0.53
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
HTR1A P08908 3/20 0.48
DRD2 P14416 3/20 0.48
DRD4 P21917 3/20 0.48
HTR1D P28221 3/20 0.48
HTR1B P28222 3/20 0.48
HTR2A P28223 3/20 0.48
HTR2C P28335 3/20 0.48
HTR7 P34969 3/20 0.48
ADRA1B P35368 3/20 0.48
DRD3 P35462 3/20 0.48
HTR2B P41595 3/20 0.48
GRIN2D O15399 1/20 0.47
GRIN3B O60391 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1347867 0.93 OPRM1 (0.62) HTR5AOPRM1OPRD1OPRK1HDAC1
SCHEMBL3341545 0.93 OPRM1 (0.62) HTR5AOPRM1OPRD1OPRK1HDAC1
SCHEMBL3342920 0.88 DHODH (0.54) HTR5AOPRM1OPRD1OPRK1HDAC1
SCHEMBL15434277 0.86 OPRM1 (0.50) HTR5AOPRM1OPRD1OPRK1HDAC1
SCHEMBL1347601 0.86 KDM4E (0.56) OPRM1OPRD1OPRK1HDAC1KDM4E
SCHEMBL1786063 0.86 KDM4E (0.56) OPRM1OPRD1OPRK1HDAC1KDM4E
SCHEMBL1347689 0.86 HDAC1 (0.61) OPRM1OPRD1OPRK1HDAC1FAAH
SCHEMBL1348560 0.86 KDM4E (0.56) OPRM1OPRD1OPRK1HDAC1KDM4E
SCHEMBL3340273 0.86 KDM4E (0.56) OPRM1OPRD1OPRK1HDAC1KDM4E
Hydrochloric Acid SCHEMBL3345306 0.85 KDM4E (0.55) OPRM1OPRD1OPRK1HDAC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors GLAXOSMITHKLINE LLC 2014-10-30 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed
EP-2054383-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS SmithKline Beecham Corporation (US) 2009-05-06 EP disclosed
WO-2008021849-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRD1, OPRK1 HTR5A 281/4885OPRM1 4/4885OPRD1 2/4885
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors OPRL1, OPRM1, OPRK1 HTR5A 204/4885OPRM1 2/4885OPRD1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.